Surfing the MASH Tsunami
Episodes
S3-E4 - NASH-TAG 2022 Wrap-up: What Did We Learn about Fatty Liver Disease and Clinical Trial Design?
13 Jan 2022
Contributed by Lukas
Send a textSurfingNASH invited four attendees to the NASH-TAG wrap up (three first-timers, two corporate executives) to focus on presentations and dis...
S3-E3 - NASH-TAG 2022 Day Two: Weight loss, Innovative Approaches and the Fireside Chat on Testing Methods
09 Jan 2022
Contributed by Lukas
Send a textSurfingNASH is covering each day of NASH-TAG 2022. This episode is a "morning after" conversation with Stephen Harrison, Louise C...
S3-E2 - NASH-TAG 2022 Day 1 Summary: NASH Combination Therapies, Artificial Intelligence, Basic Science
09 Jan 2022
Contributed by Lukas
Send a textSurfingNASH is covering each day of NASH-TAG 2022. This episode includes two separate conversations, with Stephen Harrison, Louise Campbell...
S3-E1 - Previewing NASH-TAG 2022: Are we Ready To Pivot On Testing Methods like Histopathology?
05 Jan 2022
Contributed by Lukas
Send a textIn advance of NASH-TAG 2022 this weekend, Jörn Schattenberg joins the Surfers to answer a key conference question: are we ready to pivot t...
S2-E64.3 - SurfingNASH's 2021 NAFLD Year-In-Review Covers The Growing Energy and Impact of NASH Patient Advocacy
02 Jan 2022
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Andrew Scott, Global Policy Lead for the Global Liver Institute ...
S2-E64.2 - SurfingNASH's 2021 NAFLD Year-in-Review Covers the Emerging NAFLD Public Health Agenda
02 Jan 2022
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Jeffrey Lazarus of ISGlobal and the University of Barc...
S2-E64.1 - SurfingNASH's 2021 NAFLD Year-in-Review Explores Key NASH Themes of the Year Plus the Growth of Our Podcast
01 Jan 2022
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Co-host Dr. Stephen Harrison joins Louise Campbell and Roger Gre...
S2-E64 - Stephen Harrison, Jeff Lazarus and Andrew Scott Join SurfingNASH.com's 2021 NAFLD Year-in-Review
31 Dec 2021
Contributed by Lukas
Send a textThe last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with ...
S2-E63.3 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-Life
30 Dec 2021
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Jörn Schattenberg of the University of Mainz joins Lo...
S2-E63.2 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Multidisciplinary Initiatives and the Clinical Care Pathways Paper
29 Dec 2021
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Kenneth Cusi of the University of Florida joins Louise...
S2-E63.1 - SurfingNASH's 2021 NAFLD year-in-review Covers Cirrhosis Treatment Strategies Today and NASH Drugs in Development
28 Dec 2021
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Manal Abdelmalek of Duke University joins Louise Campb...
S2-E63 - Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH's 2021 NAFLD Year-In-Review
27 Dec 2021
Contributed by Lukas
Send a textThe last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with ...
S2-E62.3 - SurfingNASH's 2021 NAFLD year-in-review Covers the Patient-Advocate Initiated and Sponsored SUNN Study
26 Dec 2021
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Fatty Liver Foundation Founder and President Wayne Eskridge join...
S2-E62.2 - SurfingNASH's 2021 NAFLD year-in-review Covers MRE and the Broader View of Non-Invasive Liver Testing
24 Dec 2021
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Alina Allen of the Mayo Clinic joins Louise Campbell a...
S2-E62.1 - SurfingNASH's 2021 NAFLD year-in-review Covers AI in Histopathology
23 Dec 2021
Contributed by Lukas
Send a textThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Dr. Mazen Noureddin, Director of the Fatty Liver Program at Ceda...
S2-E62 - Mazen Noureddin, Alina Allen And Wayne Eskridge Join SurfingNASH's 2021 NAFLD Year-in-Review
23 Dec 2021
Contributed by Lukas
Send a textThe last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with ...
S2-E61.4 - How Might the Role of Bariatric Surgery Change post-SPLENDOR?
19 Dec 2021
Contributed by Lukas
Send a textSPLENDOR lead author Ali Amirian, the Surfers and audience member Shardool Jain of Altrix Bio debate whether and when bariatric surgery mig...
S2-E61.3 - Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?
19 Dec 2021
Contributed by Lukas
Send a textA question from Ali Aminian leads the group to ponder whether cirrhosis can truly be regressed. The consensus is that many good things can ...
S2-E61.2 - What does SPLENDOR Tell Us About the Impact of Bariatric surgery on Cardiovascular and Liver Events?
18 Dec 2021
Contributed by Lukas
Send a textThe Surfers, joined by SPLENDOR lead author Ali Aminian, broaden their discussion into considering MACE and MALO patients into clinical tri...
S2-E61.1 - What does SPLENDOR Tell Us About MACE and MALO?
18 Dec 2021
Contributed by Lukas
Send a textLead author Ali Aminian shares key findings from SPLENDOR on the impact of bariatric surgery on Major Adverse Cardiovascular Events (MACE) ...
SPLENDOR Study Lead Author Discusses The Effect Of Bariatric Surgery On MACE And MALO
16 Dec 2021
Contributed by Lukas
Send a textLead author Dr. Ali Aminian of the Cleveland Clinic joins the Surfers to discuss the recent SPLENDOR Study, which focuses on the effects of...
S2-E60.3 - Previewing NASH-TAG 2022 Sessions 7-9 - Focus On Non-invasive Testing and Novel Targets
12 Dec 2021
Contributed by Lukas
Send a textNASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about the last three sessions ...
S2-E60.2 - Previewing NASH-TAG 2022 Sessions 4-6 - Focus On the Major Consortia and Artificial Intelligence
11 Dec 2021
Contributed by Lukas
Send a textNASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about important updates from t...
S2-E60.1 - Previewing NASH-TAG 2022 Sessions 1-3 -- Focus on Drug Development
11 Dec 2021
Contributed by Lukas
Send a textNASH-TAG 2022 takes place in Deer Valley Utah and on-line from January 7-8, 2022. Join Surfing NASH to learn about the important and innova...
S2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 Preview
09 Dec 2021
Contributed by Lukas
Send a textNASH-TAG 2022 Co-chair Stephen Harrison and Steering Committee Member Jörn Schattenberg review the upcoming conference, focusing on major ...
S2-E59.4 - What Can We Do To Reshape a Potentially Disasatrous Growth in Cirrhosis?
05 Dec 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell, and Roger Green to discuss the groundb...
S2-E59.3 - What's next in Driving the Global Health Agenda for NAFLD?
05 Dec 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell, and Roger Green to discuss the groundb...
S2-E59.2 - Key Issues For the NAFLD Global Health Agenda: Prevalence and Cost Data
04 Dec 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell, and Roger Green to discuss the groundb...
S2-E59.1 - How the global Health Agenda for NAFLD Was Developed
04 Dec 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbr...
S2-E59 - Discuss the Global NAFLD Agenda publication With Lead Author Jeffrey Lazarus
02 Dec 2021
Contributed by Lukas
Send a textLead author Jeffrey Lazarus joins the Surfers to discuss Advancing the Global Public Health Agenda for NAFLD, the major article recently pu...
S2-E58.3 - Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE
28 Nov 2021
Contributed by Lukas
Send a textThis episode follows S2 E43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standar...
S2-E58.2 - Focus On NASH Cirrhosis: Reviewing FALCON 2 and the Belapectin Post Hoc Analysis of Phase 2 Data
27 Nov 2021
Contributed by Lukas
Send a textThis episode follows S2 E43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standar...
S2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLD
27 Nov 2021
Contributed by Lukas
Send a textThis episode follows S2 E43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standar...
S2-E57.4 - TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?
22 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-r...
S2-E57.3 - 2021 TLMdX From AASLD: Non-conventional efficacy Metrics, Genomics of NAFLD and an Exciting Future
21 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-r...
S2-E57.2 - 2021 TLMdX From AASLD: The Path To Making NITs the "Gold Standard" for Drug Trials
21 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-r...
S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH
21 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-r...
S2-E57 - AASLD 2021 Wrap-up: Looking Back on an Eventful TLMdX
19 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week's...
S2-E56 - Day Four at the 2021 TLMdX From AASLD
16 Nov 2021
Contributed by Lukas
Send a textDrs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harris...
S2-E55 - Day Three at the 2021 TLMdX From AASLD
15 Nov 2021
Contributed by Lukas
Send a textProfs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join L...
S2-E54.3 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Priorities
13 Nov 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harriso...
S2-E54.2 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Perspectives
13 Nov 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harriso...
S2-E54.1 - Inside the Patient-Focused Drug Development meeting: Stories of Personal Experiences
13 Nov 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harriso...
S2-E58 - What's New In Clinical Trials for NASH Cirrhosis
11 Nov 2021
Contributed by Lukas
Send a textJörn Schattenberg and Mazen Noureddin join the Surfers to discuss five recently-reported or ongoing clinical trials in NASH cirrhosis. The...
S2-E54 - Go Inside a Pivotal Event: the NASH Patient-Focused Drug Development Meeting
11 Nov 2021
Contributed by Lukas
Send a textGlobal Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harriso...
S2-E53.3 - AASLD 2021 Preview: NASH Patient Management Topics Range From Drugs In Development To Applied Day-to-Day Issues
07 Nov 2021
Contributed by Lukas
Send a text In the third conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campb...
S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH
07 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-r...
S2-E53.2 - AASLD 2021 Preview: A Weekend of Broad NASH Disease/Drug Management Coverage
06 Nov 2021
Contributed by Lukas
Send a textIn the second conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbe...
S2-E53.1 - AASLD 2021 Preview: Presentations on Basic NASH Science
06 Nov 2021
Contributed by Lukas
Send a textIn the first conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbel...
S2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver Meeting
04 Nov 2021
Contributed by Lukas
Send a textManal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and previ...
S2-E52.4 - MRE Findings Suggest Flaws in Fibrosis As Endpoint
31 Oct 2021
Contributed by Lukas
Send a text Alina Allen and Ian Rowe lead the Surfers in considering biopathological shortcomings in fibrosis as a solitary endpoint. Their comments ...
S2-E52.3 - Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?
31 Oct 2021
Contributed by Lukas
Send a textAlina Allen and Stephen Harrison spearhead a discussion on how MRE results can provide a foundation for developing Subpart H Clinical Trial...
S2-E52.2 - How Liver Stiffness Measures Can Improve Practical Patient Management
30 Oct 2021
Contributed by Lukas
Send a textAlina Allen and Ian Rowe discuss how Liver Stiffness Measurements (LSM) can improve individual patient treatment in pre-cirrhotic and compe...
S2-E52.1 - MRE Predicts Long-Term Progression and Outcomes in Chronic Liver Disease Patients
30 Oct 2021
Contributed by Lukas
Send a textAlina Allen and Ian Rowe join the Surfers to discuss the recent Mayo Clinic paper, "MRE for Prediction of Long-Term Progression and Ou...
S2-E52 - Predicting Long-Term Outcomes Using MR Elastography
28 Oct 2021
Contributed by Lukas
Send a textProfessors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conver...
S2-E51.3 - More from Paris NASH: Overcoming Histopathology's flaws
24 Oct 2021
Contributed by Lukas
Send a textThe entire panel enters a discussion around histopathology's shortcomings, ranging from the fact that the NAFLD Activity score does no...
S2-E51.2 - More from Paris NASH: Precision Medicine's role in Drug Development and Patient Diagnosis
23 Oct 2021
Contributed by Lukas
Send a textStephen Harrison and Jörn Schattenberg join the conversation with questions that focus on patient treatment and drug development.The ultim...
S2-E51.1 - More from Paris NASH: precision Medicine, Stellate Cells and Hepatic Influencers
23 Oct 2021
Contributed by Lukas
Send a textScott Friedman reprises key elements from his Paris NASH talk, focusing on Precision Medicine and some key factors that affect hepatic func...
S2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott Friedman
21 Oct 2021
Contributed by Lukas
Send a textScott Friedman, the "Father of Fibrosis", and Jörn Schattenberg join the Surfers to discuss Scott's recent Paris NASH and N...
S2-E50.3 - "Dare to Dream" - How New Imaging Methods Can Change Our Future
17 Oct 2021
Contributed by Lukas
Send a textAntaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key ...
S2-E50.2 - "Seeing What Should Be" - Imaging the Liver To Assess Functioning Hepatocytes
16 Oct 2021
Contributed by Lukas
Send a textAntaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key ...
S2-E50.1 - "Potential Game Changer" - Imaging Can Provide a Dynamic View of NASH Evolution
16 Oct 2021
Contributed by Lukas
Send a textAntaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key ...
S2-E50 - "Dare to Dream" - the Exciting, Evolving World of Organ Imaging
14 Oct 2021
Contributed by Lukas
Send a textAntaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key ...
S2-E49.3 - Clinical Care Pathway: What Can Be Done Today?
10 Oct 2021
Contributed by Lukas
Send a textLast author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green...
S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data
09 Oct 2021
Contributed by Lukas
Send a textLast author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green...
S2-E49.1 - Clinical Care Pathway: How It Came To Be
09 Oct 2021
Contributed by Lukas
Send a textLast author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green...
S2-E49 - Finally, a Clinical Care Pathway For a Hidden Pandemic!
07 Oct 2021
Contributed by Lukas
Send a textLast author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green...
S2-E48.4 - Closing Thoughts On Summer: What Mattered Most?
03 Oct 2021
Contributed by Lukas
Send a textMazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." ...
S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective
03 Oct 2021
Contributed by Lukas
Send a textMazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." ...
S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"
02 Oct 2021
Contributed by Lukas
Send a textMazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." ...
S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things
02 Oct 2021
Contributed by Lukas
Send a textMazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." ...
S2-E48 - Closing Thoughts On an Eventful NASH Summer
30 Sep 2021
Contributed by Lukas
Send a textMazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer" w...
S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"
26 Sep 2021
Contributed by Lukas
Send a textProfessor Manal Abdelmalek joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She f...
S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."
25 Sep 2021
Contributed by Lukas
Send a textProfessor and epidemiologist Michelle Long joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last f...
S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."
25 Sep 2021
Contributed by Lukas
Send a textNewly-appointed Professor Ian Rowe joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few month...
S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer
24 Sep 2021
Contributed by Lukas
Send a textIan Rowe, Michelle Long and Manal Abdelmalek reveal what they consider the most important NAFLD/NASH stories of summer.Which NAFLD/NASH sto...
S2-E46.3 - Top Stories From Paris NASH: Connecting the Dots
19 Sep 2021
Contributed by Lukas
Send a textJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversa...
S2-E46.2 - Top Stories From Paris NASH: Deep Dive into Fibrosis
18 Sep 2021
Contributed by Lukas
Send a textJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversa...
S2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical Aspects
18 Sep 2021
Contributed by Lukas
Send a textJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversa...
S2-E46 - Highlights from Paris NASH
16 Sep 2021
Contributed by Lukas
Send a textJörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting, an event with...
S2-E45.3 - Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer
12 Sep 2021
Contributed by Lukas
Send a textGlobal Liver Institute President and CEO Donna Cryer joins Roger Green to discuss why recent EASL guidelines around use of non-invasive tes...
S2-E45.2 - Discussing Non-Invasive Testing and the Patient Experience with Wayne Eskridge.
11 Sep 2021
Contributed by Lukas
Send a textFatty Liver Foundation President Wayne Eskridge joins Louise Campbell and Roger Green to discuss why he is so enthusiastic about the FDA&ap...
S2-E45.1 - Discussing Fatty Liver Disease Prevalence And Patient Awareness With Anthony Villiotti
11 Sep 2021
Contributed by Lukas
Send a textNASH kNOWledge President Anthony Villiotti joins Louise Campbell and Roger Green to highlight two recent publications about NAFLD/NASH prev...
S2-E45 - Ask the Advocates: The Biggest NAFLD/NASH Story of the Summer
09 Sep 2021
Contributed by Lukas
Send a textLouise Campbell and Roger Green interview patients/patient advocates Donna Cryer, Wayne Eskridge and Anthony Villiotti about what each cons...
S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?
05 Sep 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focus...
S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord
05 Sep 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses...
S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries
04 Sep 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses...
S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses
04 Sep 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses o...
S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH
02 Sep 2021
Contributed by Lukas
Send a textDonna Cryer joins the Surfers to discuss the different effects that the Delta Variant of COVID-19 is having on different stakeholders withi...
S2-E43.4 -Rethinking Cirrhosis: A Call To Action
29 Aug 2021
Contributed by Lukas
Send a textJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfe...
S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development
29 Aug 2021
Contributed by Lukas
Send a textJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change i...
S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
28 Aug 2021
Contributed by Lukas
Send a textJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target...
S2-E43.1 - Cirrhosis - Challenges in Treating Patients
28 Aug 2021
Contributed by Lukas
Send a textJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treati...
S2-E43 - Can Cirrhosis Drive Drug Development In NASH?
26 Aug 2021
Contributed by Lukas
Send a textJörn Schattenberg joins the Surfers to discuss drug development in cirrhosis, which evolves into a discussion about how to drive NITs forw...
S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates
22 Aug 2021
Contributed by Lukas
Send a textProfessor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so import...
S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH
21 Aug 2021
Contributed by Lukas
Send a textProfessor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so import...
S2-E42.1 - FGF drugs in Development - A Promising Class of Agents
21 Aug 2021
Contributed by Lukas
Send a textProfessor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so import...
S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?
19 Aug 2021
Contributed by Lukas
Send a textProfessor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so import...
S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value
15 Aug 2021
Contributed by Lukas
Send a textCo-authors Ken Cusi and Stephen Harrison discuss reasons to be optimistic and activist about the multidisciplinary call to action regarding...
S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH
14 Aug 2021
Contributed by Lukas
Send a textCo-authors Ken Cusi and Stephen Harrison discuss critical success factors in the multidisciplinary call to action regarding the coming NASH...